Study Shows Varied Results from Different Methods of Measuring Albumin
|
By LabMedica International staff writers Posted on 21 Feb 2017 |

Image: A structural model of serum albumin (Photo courtesy of Wikimedia Commons).
A recent paper compared the accuracy of several different methods for determining levels of serum or plasma albumin, measurements, which are used to evaluate the nutritional status, kidney function, and fluid balance of dialysis patients.
Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.
Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.
“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”
The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.
The study was published in the January 2017 issue of the journal Clinical Chemistry.
Investigators at the University of Virginia Health System and Virginia Commonwealth University used 24 testing methods offered by various companies to analyze pools that had been prepared from residual patient serum and heparin plasma from patients without renal disease, and serum from patients with kidney failure before hemodialysis. Albumin was measured in all samples and in ERM-DA470k/IFCC reference material (RM) by three immunochemical, nine bromcresol green (BCG), and 12 bromcresol purple (BCP) methods.
Results revealed that two of three immunochemical procedures, five of nine BCG, and 10 of 12 BCP methods recovered the RM value within its uncertainty. One immunochemical and three BCG methods were biased versus the RM value. Random error components were small for all measurement procedures. Biases for plasma samples were generally higher than for serum samples for all method types. For most measurement procedures, biases were lower for serum from patients on hemodialysis versus patients without kidney disease.
“Nephrologists follow albumin results closely because the results are going to tell them if they need to do anything extra for these patients,” said contributing author Dr. David Bruns, professor of pathology at the University of Virginia Health System. “We know for a fact that this [albumin levels] correlates with mortality. National guidelines define what an acceptable range is and what is not acceptable.”
The investigators concluded that significant differences among immunochemical, BCG, and BCP methods compromised the interpretation of serum albumin results. Therefore, guidelines and calculations for clinical management of kidney and other diseases must consider the method used for albumin measurement until harmonization can be achieved.
The study was published in the January 2017 issue of the journal Clinical Chemistry.
Latest Clinical Chem. News
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Channels
Molecular Diagnostics
view channel
Proteomic Risk Score Predicts Kidney Disease Progression in High-Risk Patients
Chronic kidney disease progression is difficult to anticipate, limiting opportunities to intervene before irreversible decline. Risk assessment is especially uncertain for people who carry high‑risk variants... Read more
Risk Prediction Tool Enhances Genetic Testing for Li-Fraumeni Syndrome
Li-Fraumeni syndrome is a rare hereditary cancer predisposition most often driven by germline mutations in the TP53 tumor suppressor gene. Determining who should receive TP53 testing remains challenging... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
Accurate laboratory diagnosis of early Lyme disease remains challenging because serologic responses may be limited soon after infection. Missed detection at this stage can delay evaluation and management... Read more
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
Microscopy images contain rich clues about cell health, but many disease-relevant morphological differences are too subtle to see and difficult to quantify consistently. Artificial intelligence (AI) has... Read moreTechnology
view channel
Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more







